ライフサイエンスコーパス: CGM

1 CGM data came from 24 of the multiple sclerosis (mean ag

2 CGM data for weeks 3-8 of the interventions were analyse

3 CGM should be offered to all pregnant women with type 1

4 CGM were impregnated with 50,000 keratinocytes per cm2,

5 following: CGM Cr (r(s) = 0.524, P = 0.009), CGM Glx (r(s) = 0.580, P = 0.003) and NAWM Ins (r(s) = -

6 4 [CGM]; P = 0.03 [WCER]) and 2 y (P = 0.02 [CGM]; P = 0.01 [WCER]) using these 2 RRs.

7 arger than in Abeta- scans at 1 y (P = 0.04 [CGM]; P = 0.03 [WCER]) and 2 y (P = 0.02 [CGM]; P = 0.01

8 At a significance level of P < 0.05, CGM Cho, CGM and NAWM tNAA, and CGM Glx were all signifi

9 reater glycemic control as indicated by >/=1 CGM variable was associated with higher Healthy Eating I

10 skin reactions occurring in 49 (48%) of 103 CGM participants and eight (8%) of 104 control participa

11 comparable severe hypoglycaemia episodes (18 CGM and 21 control) and time spent hypoglycaemic (3% vs

12 ts in the planning pregnancy trial (two [4%] CGM and one [2%] control).

13 pants during pregnancy and in 23 (44%) of 52 CGM participants and five (9%) of 57 control participant

14 ticipants in the pregnancy trial (eight [7%] CGM, five [5%] control) and in three (3%) participants i

15 00037) and a lower proportion of time with a CGM-measured glucose concentration below 3.3 mmol/L on d

16 centration and the proportion of time with a CGM-measured glucose concentration below 3.3 mmol/L, on

17 ablished protocols; participants also wore a CGM device during the control period.

18 indicate that metabolite changes in NAWM and CGM can be detected early in the clinical course of mult

19 NAWM and CGM metabolite concentrations estimated were: choline-co

20 of P < 0.05, CGM Cho, CGM and NAWM tNAA, and CGM Glx were all significantly reduced, and NAWM Ins was

21 The most commonly available CGMs are limited by the physiology of the subcutaneous s

22 ating the sensors of a phosphorescence based CGM system into a standard insulin infusion set.

23 in 1966 [Egyptian Geological Museum, Cairo (CGM) 40237] reveal that previous estimates of its endocr

24 t a significance level of P < 0.05, CGM Cho, CGM and NAWM tNAA, and CGM Glx were all significantly re

25 omparable to that of state-of-art commercial CGM systems.

26 he surfaces of FDA-approved human commercial CGM needle-type implanted sensors in a rodent subcutaneo

27 le-port system is comparable with commercial CGM systems but further improvements are needed.

28 urised and is now comparable with commercial CGM systems regarding size, weight and wear comfort.

29 Drug-releasing and control CGM implants were compared in murine percutaneous implan

30 period compared to blank microsphere control CGM implants.

31 However, current CGM devices need further miniaturization and improved fu

32 During CGM, average percent time in hyperglycemic and hypoglyce

33 articipants were randomly assigned to either CGM in addition to capillary glucose monitoring or capil

34 ased MPhi recruitment significantly enhanced CGM performance when compared to control mice.

35 n sites, which led to significantly enhanced CGM performance, when compared to normal mice.

36 and suggest chemokine targets for enhancing CGM in vivo.

37 s sought to reduce sensor fibrosis to extend CGM functional lifetimes in subcutaneous sites.

38 arietal organoleptic traits of the fermented CGM.

39 trations were significant for the following: CGM Cr (r(s) = 0.524, P = 0.009), CGM Glx (r(s) = 0.580,

40 -) and 1.36 +/- 1.98 (Abeta+) (P = 0.02) for CGM and 0.13 +/- 1.47 and 1.32 +/- 1.75 (P = 0.01), resp

41 Associations were more consistent for CGM variables obtained concurrently with dietary intake

42 ntral, physiologically stable body space for CGM: the intraperitoneal space.

43 ndard deviation of glucose (SD glucose) from CGM and continuous overlapping net glycemic action using

44 ements in non-glycaemic health outcomes from CGM use.

45 roperly distanced reference strains generate CGMs that accurately depict evolutionary relationships,

46 roperly distanced reference strains generate CGMs that distort and reroot outgroups.

47 sis disease effects on NAWM and cortical GM (CGM) metabolite concentrations, and the relationships be

48 We collected the current from the grounded CGM probe while scanning a periodically poled lithium ni

49 therefore enable less invasive and improved CGM in patients affected by diabetes.

50 lants exhibited no significant difference in CGM fibrosis at implant sites but showed relatively stab

51 g/dL [10.0 mmol/L]), but also an increase in CGM-measured hypoglycaemia (p=0.0001 for <70 mg/dL [<3.9

52 The groups did not differ meaningfully in CGM-measured hypoglycemia or quality-of-life outcomes.

53 e feasibility of improved miniaturization in CGM based on microfluidics.

54 M plus CSII group had a greater reduction in CGM-measured mean glucose (p=0.005) and hyperglycaemia (

55 To investigate CGM-based phylogenies, we devised computer models to sim

56 This ionized CGM contains a substantial mass of heavy elements and ga

57 currently with the use of the Medtronic iPro CGM system.

58 Several combination device strategies load CGM sensors with drug payloads that release locally to t

59 is using these "comparative-genome markers" (CGMs) produced a highly unusual phylogeny with a complet

60 acterized collagen-glycosaminoglycan matrix (CGM) that has been shown to function as a dermal analog

61 Four RRs (cerebellar gray matter [CGM], whole cerebellum [WCER], pons, and subcortical whi

62 Mean CGM use was 6.7 days per week (SD 0.8) in the CGM plus C

63 reas period was associated with a lower mean CGM-measured glucose concentration on days 2-5 than was

64 The mean CGM glucose concentration was 7.8 mmol/L (SD 0.6) in the

65 s, analysed by intention to treat, were mean CGM-measured glucose concentration and the proportion of

66 The circumgalactic medium (CGM) is fed by galaxy outflows and accretion of intergal

67 A charge gradient microscopy (CGM) probe was used to collect surface screening charges

68 on charges using charge gradient microscopy (CGM).

69 P consisted of a continuous glucose monitor (CGM) and insulin pump connected to a modified smartphone

70 ssessed using continuous glucose monitoring (CGM) (n = 16), and prospective observational study compa

71 ombination of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion can be

72 (HYPOscore), continuous glucose monitoring (CGM) and in 8 subjects measurements of glucose variabili

73 ombination of continuous glucose monitoring (CGM) and insulin infusion.

74 nd 18; masked continuous glucose monitoring (CGM) data were obtained concurrently with the use of the

75 d data from a continuous glucose monitoring (CGM) device to control subcutaneous delivery of insulin

76 and time with continuous glucose monitoring (CGM) glucose concentration less than 3.3 mmol/L, analyse

77 iabetes using continuous glucose monitoring (CGM) has not been studied.

78 he benefit of continuous glucose monitoring (CGM) in the management of type 1 diabetes predominantly

79 Continuous glucose monitoring (CGM) is an important aid for diabetic patients to optimi

80 biosensor for continuous glucose monitoring (CGM) is presented.

81 Using a Continuous Glucose Monitoring (CGM) murine model we previously demonstrated that geneti

82 ectiveness of continuous glucose monitoring (CGM) on maternal glucose control and obstetric and neona

83 Continuous glucose monitoring (CGM) sensors are often advocated as a clinical solution

84 A continuous glucose monitoring (CGM) system consisting of a wireless, subcutaneously imp

85 Continuous glucose monitoring (CGM) technologies enable frequent sensing of glucose to

86 Continuous glucose monitoring (CGM) technology has improved and the devices are more wi

87 ean and SD of continuous glucose monitoring (CGM) values, percentage of CGM values in euglycemic and

88 C), combining continuous glucose monitoring (CGM) with insulin pump (continuous subcutaneous insulin

89 Continuous glucose monitoring (CGM), which studies have shown is beneficial for adults

90 fermentation of the concentrated grape must (CGM) from cv. Xinomavro using the best-performing indige

91 surements on 10 patients showed that the NIR-CGM sensor data reflects the blood reference values adeq

92 s in the pregnancy trial, and in 12 (27%) of CGM participants and 21 (37%) of control participants in

93 Adverse events occurred in 51 (48%) of CGM participants and 43 (40%) of control participants in

94 The CGM group averaged 6.7 days (SD, 0.9) of CGM use per week.

95 We found no apparent benefit of CGM in women planning pregnancy.

96 MDI or switch to CSII, with continuation of CGM, for 28 weeks.

97 To determine the effectiveness of CGM in adults with type 1 diabetes treated with insulin

98 To determine the effectiveness of CGM in adults with type 2 diabetes receiving multiple da

99 ucose monitoring (CGM) values, percentage of CGM values in euglycemic and hyperglycemic ranges, and m

100 ultiple daily insulin injections, the use of CGM compared with usual care resulted in a greater decre

101 INTERPRETATION: Use of CGM during pregnancy in patients with type 1 diabetes is

102 cose and median percent time hypoglycemic on CGM were unchanged with CSII, SD glucose and CONGA4 redu

103 range (sCTR), designed to augment pump plus CGM by preventing extreme glucose excursions; and enhanc

104 Pregnant CGM users spent more time in target (68% vs 61%; p=0.003

105 For glycemic control, rt-CGM is superior to SMBG and sensor-augmented insulin pum

106 Compared with SMBG, rt-CGM achieved a lower HbA1c level (between-group differen

107 red by continuous glucose monitoring system (CGM); the second is a model of diabetes parameter regres

108 We envision that CGM can be used in high-speed ferroelectric domain imagi

109 We found that CGMs represent a distinct class of phylogenetic markers

110 The CGM data were used to map the local electric current ori

111 The CGM group averaged 6.7 days (SD, 0.9) of CGM use per wee

112 tion, local masitinib penetration around the CGM to several hundred microns sought to reduce sensor f

113 during 6 in-clinic sessions by comparing the CGM glucose values to venous blood glucose measurements

114 1.1% at 12 weeks and 1.0% at 24 weeks in the CGM group and 0.5% and 0.4%, respectively, in the contro

115 Mean HbA1c levels decreased to 7.7% in the CGM group and 8.0% in the control group at 24 weeks (adj

116 trial, 75 adults with type 1 diabetes in the CGM group of the DIAMOND trial were randomly assigned vi

117 n <70 mg/dL was 43 min/d (IQR, 27-69) in the CGM group vs 80 min/d (IQR, 36-111) in the control group

118 In the CGM group, 93% used CGM 6 d/wk or more in month 6.

119 0.3% (SD 0.9; 3.3 mmol/mol [SD 9.8]) in the CGM plus CSII group and 0.1% (0.4; 1.1 mmol/mol [4.4]) i

120 pleted by 36 (97%) of 37 participants in the CGM plus CSII group and 35 (92%) of 38 participants in t

121 GM use was 6.7 days per week (SD 0.8) in the CGM plus CSII group and 6.9 days per week (0.3) in the C

122 mmol/L) was 791 min per day (SD 157) in the CGM plus CSII group and 741 min per day (225) in the CGM

123 Participants in the CGM plus CSII group had a greater reduction in CGM-measu

124 No participants in the CGM plus CSII group who completed the trial discontinued

125 emia occurred in one participant each in the CGM plus CSII group.

126 CSII group and 741 min per day (225) in the CGM plus MDI group (adjusted mean treatment group differ

127 up and 0.1% (0.4; 1.1 mmol/mol [4.4]) in the CGM plus MDI group (p=0.32).

128 SII group and 6.9 days per week (0.3) in the CGM plus MDI group (p=0.86).

129 glycaemia occurred in one participant in the CGM plus MDI group, and diabetic ketoacidosis and severe

130 group and 35 (92%) of 38 participants in the CGM plus MDI group.

131 cells, fibroblasts, and macrophages into the CGM from the underlying wound bed, resulting in formatio

132 this degradation mechanism is mitigated, the CGM technique can be applied to efficient energy harvest

133 Gradually, the stromal cellularity of the CGM decreased and collagen deposition and remodeling inc

134 acellular matrix, and the degradation of the CGM fibers, respectively.

135 Complete dissolution of the CGM occurred, partly as a result of degradation by an on

136 ndurance of charge collection by rubbing the CGM tip on the polymer film was limited to 20 scan cycle

137 7 participants were randomly assigned to the CGM plus CSII group and 38 participants were randomly as

138 8 participants were randomly assigned to the CGM plus MDI group.

139 Applying this understanding to the CGM-based phylogeny of M. tuberculosis, we found evidenc

140 Random assignment 2:1 to CGM (n = 105) or usual care (control group; n = 53).

141 Random assignment to CGM (n = 79) or usual care (control group, n = 79).

142 rror Grid Analysis showed similar results to CGM-devices currently on the market.

143 lly integrated using automated data transfer CGM-->algorithm-->CSII.

144 patients with type 2 diabetes currently use CGM, these results support an additional management meth

145 In the CGM group, 93% used CGM 6 d/wk or more in month 6.

146 insulin injections for type 2 diabetes used CGM on a daily or near-daily basis for 24 weeks and had

147 to CSII in adults with type 1 diabetes using CGM.

148 difference in HbA1c in pregnant women using CGM (mean difference -0.19%; 95% CI -0.34 to -0.03; p=0.

149 The primary outcome was CGM-measured time in the glucose concentration range of

150 The correlation of clinical impairment with CGM Cr and Glx but not tNAA suggests that it is more clo

151 lycemia at less than 70 mg/dL, measured with CGM for 7 days at 12 and 24 weeks.

152 gnancy) to capillary glucose monitoring with CGM (108 pregnant and 53 planning pregnancy) or without

153 I 0.7-1.6; p<0.0001), and the mean time with CGM glucose concentration less than 3.3 mmol/L was 0.6%